Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B A Hadaschik

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Langenbeck'S Archives of Surgery|December 23, 2021
Comparative analysis of Bricker versus Wallace ureteroenteric anastomosis and identification of predictors for postoperative ureteroenteric strictureU Krafft, O Mahmoud, J Hess, et al.
Der Urologe. Ausg. A|May 12, 2016
[Multiparametric MRI and MRI-TRUS fusion biopsy in patients with prior negative prostate biopsy]C Kesch, J P Radtke, F Distler, et al.
Pathology Oncology Research : POR|June 29, 2019
STIP1 Tissue Expression Is Associated with Survival in Chemotherapy-Treated Bladder Cancer PatientsU Krafft, S Tschirdewahn, J Hess, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 2, 2020
First-in-man intraoperative Cerenkov luminescence imaging for oligometastatic prostate cancer using <sup>68</sup>Ga-PSMA-11Christopher Darr, U Krafft, W P Fendler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2012
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesionsA Afshar-Oromieh, A Malcher, M Eder, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 6, 2013
Reply to Reske et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesionsA Afshar-Oromieh, A Malcher, M Eder, et al.
Molecular Imaging and Biology|September 5, 2019
Whole-Body Integrated [<sup>68</sup>Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of ReferenceNika Guberina, P Hetkamp, H Ruebben, et al.
Prostate Cancer and Prostatic Diseases|May 18, 2016
Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillanceJ P Radtke, T H Kuru, D Bonekamp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2019
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancerE J Small, F Saad, S Chowdhury, et al.
Prostate Cancer and Prostatic Diseases|June 17, 2015
Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidanceJ P Radtke, S Boxler, T H Kuru, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Langenbeck'S Archives of Surgery|December 23, 2021
Comparative analysis of Bricker versus Wallace ureteroenteric anastomosis and identification of predictors for postoperative ureteroenteric strictureU Krafft, O Mahmoud, J Hess, et al.
Der Urologe. Ausg. A|May 12, 2016
[Multiparametric MRI and MRI-TRUS fusion biopsy in patients with prior negative prostate biopsy]C Kesch, J P Radtke, F Distler, et al.
Pathology Oncology Research : POR|June 29, 2019
STIP1 Tissue Expression Is Associated with Survival in Chemotherapy-Treated Bladder Cancer PatientsU Krafft, S Tschirdewahn, J Hess, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 2, 2020
First-in-man intraoperative Cerenkov luminescence imaging for oligometastatic prostate cancer using <sup>68</sup>Ga-PSMA-11Christopher Darr, U Krafft, W P Fendler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2012
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesionsA Afshar-Oromieh, A Malcher, M Eder, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 6, 2013
Reply to Reske et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesionsA Afshar-Oromieh, A Malcher, M Eder, et al.
Molecular Imaging and Biology|September 5, 2019
Whole-Body Integrated [<sup>68</sup>Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of ReferenceNika Guberina, P Hetkamp, H Ruebben, et al.
Prostate Cancer and Prostatic Diseases|May 18, 2016
Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillanceJ P Radtke, T H Kuru, D Bonekamp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2019
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancerE J Small, F Saad, S Chowdhury, et al.
Prostate Cancer and Prostatic Diseases|June 17, 2015
Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidanceJ P Radtke, S Boxler, T H Kuru, et al.
Pageof 4